Dr. Abidi Pharmaceuticals has launched the highly effective and innovative drug Tirzepatide under the brand name Zcorpa®. Zcorpa® is an effective, high-quality, and easy-to-use injectable treatment designed for efficient weight management, glycemic control, and the treatment of moderate-to-severe Obstructive Sleep Apnea (OSA) in individuals living with obesity.

Amir Razavian, CEO of Dr. Abidi Pharmaceuticals, stated regarding the launch of Zcorpa®: “As Dr. Abidi Pharmaceuticals embarks on its 80th year of operation, and following a decade of providing innovative and high-quality treatments in the field of cardiometabolic diseases, we are introducing Zcorpa® to the medical community with the aim of facilitating the effective management of weight loss and Type 2 Diabetes.”

Clinical trial results have demonstrated that a once-weekly injection of Tirzepatide can lead to a weight reduction of over 20% in individuals with obesity and overweight. In some instances, the outcomes of this simple and effective method are comparable to those of invasive weight-loss procedures. Furthermore, significant reductions in HbA1c levels in individuals with Type 2 Diabetes, coupled with a favorable safety profile, stand as other major achievements of this novel therapy. Additionally, symptomatic improvement has been reported in a subset of patients suffering from obesity-related Obstructive Sleep Apnea.

With the introduction of advanced medications from the GLP-1 class, the global approach to treating obesity and diabetes has undergone a fundamental transformation. As one of the most innovative drugs in this field, Zcorpa® is the first known compound to act simultaneously on both GLP-1 and GIP receptors (dual agonist). It targets multiple key metabolic pathways concurrently through mechanisms such as enhancing insulin secretion and sensitivity, regulating glucagon, delaying gastric emptying, and promoting a feeling of satiety.

Today, obesity and diabetes are considered among the most critical global health challenges. Driven by sedentary lifestyles and poor dietary patterns, the prevalence of these conditions is continuously rising. Obesity, which has been recognized as a chronic disease in recent years, can be associated with numerous complications, including cardiovascular diseases, mobility disorders, Obstructive Sleep Apnea, and an increased risk of mortality. Despite extensive therapeutic efforts over the past decades, many conventional methods have failed to exert a sustained and significant impact on controlling this disease.

The close correlation between obesity and Type 2 Diabetes is also of paramount importance. Over 90% of diabetes cases worldwide are Type 2, and a substantial proportion of these patients live with overweight or obesity. This comorbidity has made the integrated management of weight, blood glucose, and cardiovascular risks a top priority for modern therapies.

Dr. Abidi Pharmaceuticals has been a pioneer in providing innovative treatments for cardiometabolic diseases for over 12 years. Now, at the dawn of its 80th year of operation, the production of Zcorpa® marks another significant milestone in increasing Iranian patients’ access to state-of-the-art global treatments, particularly in the management of obesity and Type 2 Diabetes.

 

References:

  • Tirzepatide FDA Label 2024. Reference ID: 5472245
  • 2025 Oct 4;406(10511):1484-1496
  • N Engl J Med. 2025 Mar 6;392(10):958-971
  • J. Res. Med. Dent. Sci. 2022, 10, 122–130